Anti-CD1a CAR-T Cell Therapy(Xuzhou Medical University)

N/A

Report date: 2023/03/03 20:00:36

Base Information

Drug NameAnti-CD1a CAR-T Cell Therapy(Xuzhou Medical University)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Source of cells > PMBC-derivedCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionAnti-T-cell surface glycoprotein CD1a

TargetsT-cell surface glycoprotein CD1a

Therapy Area/IndicationsPrecursor Cell Lymphoblastic Leukemia-Lymphoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaPhase 2 Clinical

Originator CompaniesXuzhou Medical University (Xzmu)

China Registration ClassN/A

Develop Information

Active CompaniesThe Affiliated Hospital Of Xuzhou Medical University

Inactive CompaniesN/A

Active IndicationsPrecursor Cell Lymphoblastic Leukemia-Lymphoma

Inactive IndicationsN/A

Other Information

ATC CodeN/A